Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

Abstract

Background and ObjectivesOral delayed-release dimethyl fumarate (DMF) is not recommended during pregnancy and should only be used if the potential benefit justifies the potential fetal risk. Although DMF was well tolerated in clinical trials with consistent safety results in postmarketing surveillance, data are limited in pregnant women. The objective was to provide pregnancy outcomes and DMF exposure information from an interim analysis from a prospective, international registry (TecGistry; NCT01911767).MethodsWomen exposed to DMF from the first day of their last menstrual period before conception or during pregnancy were evaluated. Data were obtained at enrollment; 6−7 months' gestation; 4 weeks after estimated due date; and 4, 12, and 52 weeks after birth. Outcomes included live births, gestational size, pregnancy loss, birth defects, and infant or maternal death after delivery. Outcomes were analyzed cumulatively from October 30, 2013 (the start of TecGistry), to April 8, 2020.ResultsOf 345 enrolled patients, median (range) age was 32 (20–43) years. The mean (SD) duration of gestational weeks of DMF exposure was 4.9 (3.8). Most infants were full-term at birth (n = 249/274; 91%) and of average gestational size (n = 190/232; 82%). Of 351 outcomes, 277 were live births; 17 (5%) spontaneous abortions (95% confidence interval [CI] 2.6%–7.1%), including 1 (<1%) molar and 1 (<1%) ectopic pregnancy, were reported. There were 8 (2.9% [95% CI 1.3%–5.6%]) adjudicator-confirmed birth defects among the 277 live births.DiscussionInterim results from this large registry indicate that early DMF exposure was not significantly associated with adverse pregnancy outcomes. Outcomes are consistent with previous smaller reports and with the general population.Trial Registration InformationTecGistry; clinical trial registration number: NCT01911767.

Multiple sclerosis impact on pregnancy: An update on management issues

“…Also, the previous evidence showed delayed ossification and embryo toxicity in pregnant rats with very high dosages [67]. In the Hellwig et al [68] study, of 351 pregnancies, 277 were live births; 17 spontaneous abortions, including one molar and one ectopic pregnancy, were reported.…”

Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society

“…There is limited data on exposure to DMF in the first trimester of pregnancy (≈300 cases) but no signal of adverse outcomes. 177,178 After oral intake, DMF is rapidly transformed into monomethyl fumarate; its half-life is only 1 hour; monomethyl fumarate has therefore been eliminated within 24 hours.…”

Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders

“…Apart from being tested clinically, as mentioned before, DMF is the only Nrf2 inducer approved exclusively for CNS-related disorders. Although the safety and efficacy of DMF have been shown with large cohorts and even in pregnant women ( 198 ), it causes substantial side effects such as a reduced number of lymphocytes ( 199 ). DMF or other electrophilic Nrf2 activators induce off-target side effects, which has been explained by S-alkylation of cysteine thiols non-specifically and subsequent deficiency of anti-oxidative glutathione ( 200 ).…”